Clinical trial

Etrasimod in Patients with moderately to severely active ulcerative colitis – Learnings from the Phase 3 ELEVATE UC Clinical Program

Pfizer Inflammation and Immunology and Specialty Care

DOI: 10.26303/c4mp-wy74

What is it about?

The ELEVATE UC clinical program evaluated etrasimod, a selective sphingosine 1 phosphate (S1P) receptor modulator, as a treatment for adults with moderately to severely active ulcerative colitis. The main results were published by Sandborn et al. and are based on two global, randomized, double‑blind, placebo‑controlled phase 3 trials: ELEVATE UC 12 and ELEVATE UC 52.

ELEVATE UC 12 assessed short term induction over 12 weeks, while ELEVATE UC 52 used a treat through design with a 12 week induction phase followed by 40 weeks of maintenance, allowing continuous assessment of efficacy over one year. Patients received once daily oral etrasimod 2mg or placebo.

The study population included adults with active ulcerative colitis who had an inadequate response, loss of response, or intolerance to prior therapies. This included patients who were naïve to advanced therapies as well as those previously treated with biologics or JAK inhibitors. Patients with different disease extents were enrolled, ranging from isolated proctitis to more extensive colitis.

Efficacy assessments focused on clinical remission, symptom improvement, and healing of the intestinal lining measured by endoscopy. Safety was monitored throughout the trials. Key subgroup analyses included patients with isolated proctitis, biologic‑ or JAK‑inhibitor–experienced patients and patients achieving steroid-free outcomes.

Why is it important?

Findings from the phase 3 ELEVATE UC studies demonstrate the efficacy and safety of etrasimod and support its role within the evolving therapeutic landscape of ulcerative colitis. In the clinical trials etrasimod significantly increased rates of clinical remission compared with placebo, both after 12 weeks of induction and after 52 weeks of continuous treatment. Patients experienced meaningful improvements in rectal bleeding, stool frequency, and healing of the intestinal mucosa.

A key finding for clinical practice is the durability of response. In the 52 week study, remission rates were maintained over time, and all patients who were in remission at one year were also steroid free, highlighting the potential to achieve sustained disease control without ongoing corticosteroid use. Reducing steroid dependence remains a major goal in ulcerative colitis management.

Subgroup analyses showed consistent treatment effects and safety across clinically relevant populations, including patients with isolated proctitis as well as in patients previously treated with biologics or JAK inhibitors. In addition, the consistent efficacy and safety profile seen in patients without prior advanced therapy support the consideration of etrasimod as a treatment option earlier in the management of appropriate adults with moderately to severely active ulcerative colitis.

With once daily oral dosing, sustained efficacy, steroid free remission, and a well-characterized safety profile, etrasimod helps address key unmet needs and expands treatment options for healthcare professionals managing ulcerative colitis.

EM-GLB-EUC-0062 | March 2026 Page published: 11-April-2026

Resources16 total

Who is involved?